CDKN1A and cancer: We also showed that our MELK inhibitor (OTS167) activated p53 and p21 in the cancer cell line with wild-type p53, but unexpectedly we observed activation of p21 in the cancer cell lines even with p53 mutation [8], indicating a possibility of p53-independent p21 activation mechanism regulated by MELK in cancer cells.